In summary, TCRP1/AKT/FOXO3a axis provides a complementary and more comprehensive understanding of NSCLC and offers an opportunity to translation of basic research to potential treatment in the clinic. This evidence concerns the gene FAM168A and non-small cell lung carcinoma.